214 related articles for article (PubMed ID: 36545783)
1. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Speckmaier S; Barad E; Moran-Garcia N; Datwani S; Duncan MC; Kalikawe R; Ennis S; Young L; Ganase B; Omondi FH; Umviligihozo G; Dong W; Toy J; Sereda P; Burns L; Costiniuk CT; Cooper C; Anis AH; Leung V; Holmes D; DeMarco ML; Simons J; Hedgcock M; Prystajecky N; Lowe CF; Romney MG; Barrios R; Guillemi S; Brumme CJ; Montaner JSG; Hull M; Harris M; Niikura M; Brockman MA; Brumme ZL
AIDS; 2023 Apr; 37(5):709-721. PubMed ID: 36545783
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL;
AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806
[TBL] [Abstract][Full Text] [Related]
3. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
Mwimanzi F; Lapointe HR; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Burns L; Young L; Leung V; Ennis S; Brumme CJ; Montaner JSG; Dong W; Prystajecky N; Lowe CF; DeMarco ML; Holmes DT; Simons J; Niikura M; Romney MG; Brumme ZL; Brockman MA
Open Forum Infect Dis; 2023 Mar; 10(3):ofad073. PubMed ID: 36910697
[TBL] [Abstract][Full Text] [Related]
4. People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.
Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Umviligihozo G; Kalikawe R; Speckmaier S; Moran-Garcia N; Datwani S; Duncan MC; Agafitei O; Ennis S; Young L; Ali H; Ganase B; Omondi FH; Dong W; Toy J; Sereda P; Burns L; Costiniuk CT; Cooper C; Anis AH; Leung V; Holmes DT; DeMarco ML; Simons J; Hedgcock M; Prystajecky N; Lowe CF; Pantophlet R; Romney MG; Barrios R; Guillemi S; Brumme CJ; Montaner JSG; Hull M; Harris M; Niikura M; Brockman MA; Brumme ZL
J Infect Dis; 2023 Apr; 227(7):838-849. PubMed ID: 35668700
[TBL] [Abstract][Full Text] [Related]
5. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.
Costiniuk CT; Singer J; Lee T; Galipeau Y; McCluskie PS; Arnold C; Langlois MA; Needham J; Jenabian MA; Burchell AN; Samji H; Chambers C; Walmsley S; Ostrowski M; Kovacs C; Tan DHS; Harris M; Hull M; Brumme ZL; Lapointe HR; Brockman MA; Margolese S; Mandarino E; Samarani S; Vulesevic B; Lebouché B; Angel JB; Routy JP; Cooper CL; Anis AH;
AIDS; 2023 Oct; 37(12):F25-F35. PubMed ID: 37534695
[TBL] [Abstract][Full Text] [Related]
6. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
8. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
9. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
[TBL] [Abstract][Full Text] [Related]
10. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Waterworth R; Umviligihozo G; Ennis S; Young L; Dong W; Kirkby D; Burns L; Leung V; Holmes DT; DeMarco ML; Simons J; Matic N; Montaner JSG; Brumme CJ; Prystajecky N; Niikura M; Lowe CF; Romney MG; Brockman MA; Brumme ZL
Front Immunol; 2022; 13():947021. PubMed ID: 36148225
[TBL] [Abstract][Full Text] [Related]
11. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.
Heftdal LD; Pérez-Alós L; Hasselbalch RB; Hansen CB; Hamm SR; Møller DL; Pries-Heje M; Fogh K; Gerstoft J; Grønbæk K; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Sabin C; Nielsen SD
EBioMedicine; 2023 Jul; 93():104661. PubMed ID: 37331161
[TBL] [Abstract][Full Text] [Related]
13. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
[TBL] [Abstract][Full Text] [Related]
14. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; de la Concepción MLR; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
[TBL] [Abstract][Full Text] [Related]
15. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S; Fox J; Tipoe T; Longet S; Tipton T; Abeywickrema M; Adele S; Alagaratnam J; Ali M; Aley PK; Aslam S; Balasubramanian A; Bara A; Bawa T; Brown A; Brown H; Cappuccini F; Davies S; Fowler J; Godfrey L; Goodman AL; Hilario K; Hackstein CP; Mathew M; Mujadidi YF; Packham A; Petersen C; Plested E; Pollock KM; Ramasamy MN; Robinson H; Robinson N; Rongkard P; Sanders H; Serafimova T; Spence N; Waters A; Woods D; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Winston A; Hill AVS; Gilbert SC; Carroll M; Pollard AJ; Lambe T; Ogbe A; Frater J
Clin Infect Dis; 2023 Jan; 76(2):201-209. PubMed ID: 36196614
[TBL] [Abstract][Full Text] [Related]
16. Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
Yamamoto S; Matsuda K; Maeda K; Horii K; Okudera K; Oshiro Y; Inamura N; Nemoto T; Takeuchi JS; Li Y; Konishi M; Tsuchiya K; Gatanaga H; Oka S; Mizoue T; Sugiyama H; Aoyanagi N; Mitsuya H; Sugiura W; Ohmagari N
J Infect Dis; 2023 Dec; 228(12):1652-1661. PubMed ID: 37756608
[TBL] [Abstract][Full Text] [Related]
17. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
18. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
19. Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.
Casado-Fernández G; Cantón J; Nasarre L; Ramos-Martín F; Manzanares M; Sánchez-Menéndez C; Fuertes D; Mateos E; Murciano-Antón MA; Pérez-Olmeda M; Cervero M; Torres M; Rodríguez-Rosado R; Coiras M
Front Immunol; 2024; 15():1362621. PubMed ID: 38812512
[TBL] [Abstract][Full Text] [Related]
20. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
